John F. Neylan - 20 Dec 2021 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role
Senior Vice President and Chief Medical Officer
Signature
/s/ Jennifer J. Rhodes, as attorney-in fact for John F. Neylan
Issuer symbol
ELTX
Transactions as of
20 Dec 2021
Net transactions value
-$938
Form type
4
Filing time
21 Dec 2021, 15:25:24 UTC
Previous filing
22 Nov 2021
Next filing
04 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELTX Common Stock Sale $938 -358 -1% $2.62 35,136 20 Dec 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted on March 18, 2021 by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer.

Remarks:

Senior Vice President and Chief Medical Officer